Alle Storys
Folgen
Keine Story von MediGene AG mehr verpassen.

MediGene AG

euro adhoc: MediGene AG
MediGene intends to raise EUR16 MM in a share capital increase (E)

  Disclosure announcement transmitted by euro adhoc.
  The issuer is responsible for the content of this announcement.
Martinsried - San Diego, March 4, 2004. The German-American biotech
company MediGene AG (Frankfurt, Prime Standard: MDG) has finalized a
three-step corporate action to increase cash available by approx. 16
million EUR. The first step will be a share capital increase by 10 %
through a private placement under participation of Techno Venture
Management (TVM) without subscription rights for shareholders.
Approx. 1.1 million new shares will be issued at the average market
price of the past five trading days, that is 6.80 EUR per share. In a
second capital increase of 10 %, MediGene will submit an offer to
current shareholders for again approx. 1.1 million new shares at 6.80
EUR each. In addition, MediGene will offer convertible bonds at the
amount of 1.5 million EUR, which can be subscribed to by shareholders
for 1 EUR each.  The conversion price is 7.50 EUR per share. The
convertible bonds bear 4 % interest annually during the 4 years to
maturity. Conversion is possible after a period of 12 months.
MediGene can ask for conversion under certain circumstances.
Subscription period wil be March 6 - 19, 2004.
According company´s statements the capital increase measures will
extend the financial scope for MediGene AG and increase the current
amount of cash to about 40 million EUR.
Due to these measures, the number of MediGene shares will rise from
11,228,362 to 13,474,032. The capital increase measures will be
carried out with authorized and conditional capital. No further
shareholder´s resolution is needed.
Contact:
MediGene AG
Email:  	investor@medigene.com 
Fax:	++49 - 89 - 85 65- 2920	
Julia Hofmann, Public Relations, Tel.:++49 - 89 - 85 65- 3324 
Dr. Michael Nettersheim, Investor Relations, Tel.:++49-89-8565-2946
end of announcement        euro adhoc 04.03.2004

Further inquiry note:

Julia Hofmann
Tel.: +49 (0)89 8565 3324
E-Mail: j.hofmann@medigene.com

Branche: Biotechnology
ISIN: DE0005020903
WKN: 502090
Index: CDAX, Prime All Share, Prime Standard, Technologie All Share
Börsen: Frankfurter Wertpapierbörse / regulated dealing
Niedersächsische Börse zu Hannover / free trade
Berliner Wertpapierbörse / free trade
Bayerische Börse / free trade
Hamburger Wertpapierbörse / free trade
Bremer Wertpapierbörse (BWB) / free trade
Börse Düsseldorf / free trade
Baden-Württembergische Wertpapierbörse / free trade

Weitere Storys: MediGene AG
Weitere Storys: MediGene AG